TR subscribers: I'll be in Cambridge, Mass. Wed pm Mar. 29 for a special event, announcing my next biotech community campaign. Email me to request an invite.

PR tip: I don't take PR pitches for guests on The Long Run. But I do offer sponsorship opportunities on the show. For more information, please see Stephanie Barnes. timmermanreport.com/team/stephanie…

Welcome to the AI Irruption. By David Shaywitz timmermanreport.com/2023/03/welcom…

An in-depth look into the early decisions at CRISPR Therapeutics that set the wheels in motion for the first CRISPR gene-edited therapy for sickle cell disease. By the first CSO, Bill Lundberg. (Sub. Req.) timmermanreport.com/2023/04/transl…

Preserving Biotech's Social Contract. Guest editorial by oncology executive Steve Potts. (Free, shareable) timmermanreport.com/2023/05/preser…

From Structural Biology to Structuring Biotech Startups. DebPalestrant of 5AM Ventures is the latest guest on The Long Run podcast. timmermanreport.com/2023/05/from-s…

The bottleneck in primary care is emerging issue that has an effect on biopharma. By @alexharding7 timmermanreport.com/2023/06/biopha…

Lessons Learned from a $1B Acquisition. By Ron Cooper, former CEO of Albireo Pharma. timmermanreport.com/2023/07/lesson…

Neumora Advances to Phase III with Depression Drug with Novel Mechanism; Hires AbbVie Vet as CEO. timmermanreport.com/2023/07/neumor…

Met a grad student this morning who asked for a student discount. Yes! I do offer this option. If you want to bolster your biotech education by staying up to date on Timmerman Report, see me.

Challenges of Adopting Data Science / AI in Biotech & Pharma. By Brandon Allgood. timmermanreport.com/2023/08/challe…

Nimble Pharmas & Plodding Biotechs. The IRA has Flipped the Script. By Alex Harding (Sub. Req.) timmermanreport.com/2023/11/nimble…

The Cultures of Large and Small Pharmas, plus, Can They Overcome the 'Productivity Paradox' and Seize the AI Moment. By TR healthtech columnist David Shaywitz timmermanreport.com/2023/12/the-cu…

From the archives: Read about RayzeBio's $45 million Series A and founding plan. (Oct. 2020). timmermanreport.com/2020/10/rayzeb… Acquired today by Bristol Myers Squibb for $4.1 billion.

Candid Feedback: It's Harder to Get from Investors Than Money. By Bernat Olle 🇺🇦 timmermanreport.com/2024/01/one-th…

Madrigal's Historic 1st for MASH, IFM's Hat Trick, & BIO on Election Defense. The weekly Frontpoints column. timmermanreport.com/2024/03/madrig…

Boundless IPO, Merck's Acceleron Win & Moderna's $750M Flu Vaccine Boost. The Frontpoints column. (Sub. Req.) timmermanreport.com/2024/03/boundl…

How CymaBay Survived a Safety Scare. timmermanreport.com/2024/04/how-cy…

A ProfoundBio Windfall, Amylyx Yanks ALS Drug, & Verve's Rough Patch. timmermanreport.com/2024/04/a-prof…

Third Rock-backed Marea Raises $190M to Take Aim at Remnant Cholesterol. (Sub. Req). timmermanreport.com/2024/06/marea-…